WO1993015097A1 - Reactif et procede pour la determination de l'activite d'enzymes glycohydrolitiques - Google Patents
Reactif et procede pour la determination de l'activite d'enzymes glycohydrolitiques Download PDFInfo
- Publication number
- WO1993015097A1 WO1993015097A1 PCT/US1993/000988 US9300988W WO9315097A1 WO 1993015097 A1 WO1993015097 A1 WO 1993015097A1 US 9300988 W US9300988 W US 9300988W WO 9315097 A1 WO9315097 A1 WO 9315097A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glycohydrolytic
- pyrene
- enzyme
- carbohydrate
- compound
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 50
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 24
- 239000003153 chemical reaction reagent Substances 0.000 title description 7
- 238000012360 testing method Methods 0.000 claims abstract description 31
- 239000012085 test solution Substances 0.000 claims abstract description 18
- 230000003287 optical effect Effects 0.000 claims abstract description 14
- 230000002596 correlated effect Effects 0.000 claims abstract description 9
- 102000053187 Glucuronidase Human genes 0.000 claims description 37
- 108010060309 Glucuronidase Proteins 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 30
- 150000001720 carbohydrates Chemical group 0.000 claims description 16
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 10
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 10
- 238000009739 binding Methods 0.000 claims description 9
- 150000001719 carbohydrate derivatives Chemical group 0.000 claims description 9
- 150000002772 monosaccharides Chemical group 0.000 claims description 9
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 8
- 150000003863 ammonium salts Chemical class 0.000 claims description 8
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 7
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 150000001340 alkali metals Chemical class 0.000 claims description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 claims description 2
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 125000000600 disaccharide group Chemical group 0.000 claims 1
- 150000008498 β-D-glucosides Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 230000015572 biosynthetic process Effects 0.000 abstract description 15
- 239000002253 acid Substances 0.000 abstract description 12
- ORUDTFXLZCCWNY-UHFFFAOYSA-N pyrene-1,2,3-trisulfonic acid Chemical class C1=CC=C2C=CC3=C(S(O)(=O)=O)C(S(=O)(=O)O)=C(S(O)(=O)=O)C4=CC=C1C2=C43 ORUDTFXLZCCWNY-UHFFFAOYSA-N 0.000 abstract description 6
- 208000028169 periodontal disease Diseases 0.000 abstract description 4
- OBJOZRVSMLPASY-UHFFFAOYSA-N 8-hydroxypyrene-1,3,6-trisulfonic acid Chemical compound C1=C2C(O)=CC(S(O)(=O)=O)=C(C=C3)C2=C2C3=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1 OBJOZRVSMLPASY-UHFFFAOYSA-N 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 38
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 12
- 239000008367 deionised water Substances 0.000 description 11
- 229910021641 deionized water Inorganic materials 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 9
- 239000001632 sodium acetate Substances 0.000 description 9
- 235000017281 sodium acetate Nutrition 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 239000004471 Glycine Substances 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000012491 analyte Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229930182480 glucuronide Natural products 0.000 description 4
- 150000008134 glucuronides Chemical class 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- -1 o- tolyl Chemical group 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 3
- BBEAQIROQSPTKN-UHFFFAOYSA-N antipyrene Natural products C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- DLOBKMWCBFOUHP-UHFFFAOYSA-N pyrene-1-sulfonic acid Chemical compound C1=C2C(S(=O)(=O)O)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 DLOBKMWCBFOUHP-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- JIEINYQEXWLMCU-UHFFFAOYSA-N 7-bromo-3-hydroxy-n-(2-methoxyphenyl)naphthalene-2-carboxamide Chemical compound COC1=CC=CC=C1NC(=O)C1=CC2=CC(Br)=CC=C2C=C1O JIEINYQEXWLMCU-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- XGDPKUKRQHHZTH-UHFFFAOYSA-N Methyl 2,5-dihydroxybenzoate Chemical group COC(=O)C1=CC(O)=CC=C1O XGDPKUKRQHHZTH-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003444 phase transfer catalyst Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- FXJYOZKDDSONLX-XADSOVDISA-N (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[4-[1-(4-hydroxyphenyl)-3-oxo-2-benzofuran-1-yl]phenoxy]oxane-2-carboxylic acid Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=CC=C(C2(C3=CC=CC=C3C(=O)O2)C=2C=CC(O)=CC=2)C=C1 FXJYOZKDDSONLX-XADSOVDISA-N 0.000 description 1
- 0 *=Cc1c(ccc(c(*#I)c2)c3c(cc4)c2O)c3c4c(IO)c1 Chemical compound *=Cc1c(ccc(c(*#I)c2)c3c(cc4)c2O)c3c4c(IO)c1 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QJFWLRHTUHXQJW-FVCCEPFGSA-N [(2r,3r,4s,5r)-3,4,5-triacetyloxy-6,6-dibromooxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1OC(Br)(Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O QJFWLRHTUHXQJW-FVCCEPFGSA-N 0.000 description 1
- CYAYKKUWALRRPA-RGDJUOJXSA-N [(2r,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-bromooxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@H](Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O CYAYKKUWALRRPA-RGDJUOJXSA-N 0.000 description 1
- CYAYKKUWALRRPA-HTOAHKCRSA-N [(2r,3s,4s,5r,6r)-3,4,5-triacetyloxy-6-bromooxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@H](Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O CYAYKKUWALRRPA-HTOAHKCRSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- CHQVQXZFZHACQQ-UHFFFAOYSA-M benzyl(triethyl)azanium;bromide Chemical compound [Br-].CC[N+](CC)(CC)CC1=CC=CC=C1 CHQVQXZFZHACQQ-UHFFFAOYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- 125000005640 glucopyranosyl group Chemical group 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002951 idosyl group Chemical class C1([C@@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 125000001209 o-nitrophenyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])[N+]([O-])=O 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 1
- FXJYOZKDDSONLX-UHFFFAOYSA-N phenolphthalein-mono-beta-glucuronic acid Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC1=CC=C(C2(C3=CC=CC=C3C(=O)O2)C=2C=CC(O)=CC=2)C=C1 FXJYOZKDDSONLX-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 229930028731 β-maltose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/80—Fluorescent dyes, e.g. rhodamine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
Definitions
- the present invention relates to the determination of glycohydrolytic enzymes.
- the present invention relates to pyrene-trisulfonic acid derivatives of carbohydrates and the use thereof in assays for the determination of glycohydrolytic enzymes such as ⁇ -glucuronidase.
- glycohydrolytic enzymes are a class of enzymes which have been employed in various diagnostic applications, such as for measuring PMN phagocytic activity and periodontal disease activity, for classifying bacteria, and as a component of conjugates in enzyme immunoassay procedures.
- determination of glycohydrolytic enzymes involves the use of a hydrophobic substrate.
- substrates include synthetic compounds such as phenolphthalein glucuronide and methylumbelliferyl glucuronide, and metabolic products such as the glucuronides of steroids and bilirubin.
- hydrolytic enzymes such as ⁇ -glucuronidase, for highly polar substrates has not been described.
- esters show violet fluorescence ( ⁇ ma ⁇ 390 and 408 nanometers) when excited below 385 nanometers, they do not fluoresce when excited at 460 nanometers.
- hydrolysis of such esters results in the formation of an anion of the formula [II]:
- [IV] The methyl(aryl-tri-0-acetyl-(H ⁇ )-D-glucopyranosid)-uronates described by Bollenback, et al., include those where R in the formula [V] is phenyl, 1-naphthyl and 2-naphthyl, and die alpha anomers of the compounds of the formula [IN] and [N] where R is o-chlorophenyl, p-chlorophenyl, o-bromophenyl, p-bromophenyl, o-iodophenyl, o- tolyl, m-tolyl, p-tolyl, o-hydroxyphenyl, 1-naphthyl, 2-naphthyl, methyl gentisate and o-nitrophenyl are also described.
- the present invention provides novel pyrene-trisulfonate derivatives, the synthesis of such derivatives, and the use thereof for the determination of glycohydrolytic enzyme activity.
- the pyrene- trisulfonate derivatives of the present invention are of the general formula [VI]:
- R is a carbohydrate, or a carbohydrate derivative, which is capable of binding to a glycohydrolytic enzyme and comprises from 1 to 10 linked monosaccharide units, and wherein Mi, M 2 , and M 3 , which can be the same or different, are an alkali metal, hydrogen, ammonium, alkyl-substituted ammonium, or aryl-substituted ammonium.
- R is ⁇ -D-glucuronide, ⁇ -D-giucoside, ⁇ -D- galactoside, ⁇ -D-maltoside, a monosaccharide, or a disaccharide.
- the compound of formula [VI] does not fluoresce when excited with light having a wavelength of 460 nm, whereas the aglycon moiety thereof does fluoresce at such wavelength and, accordingly, is especially useful for the determination of glycohydrolytic enzymes.
- glycohydrolytic enzymes include, but are not intended to be limited to, ⁇ - glucuronidase, ⁇ -glucosidase, ⁇ -galactosidase, and the like.
- the method for determining a glycohydrolytic enzyme according to the present invention comprises the steps of:
- a test solution comprising a test sample containing the glycohydrolytic enzyme and the compound of formula VI, wherein the glycohydrolytic enzyme binds to R and causes the hydrolysis of the compound to result in the formation of free 8- hydroxy-l ,3,6-pyrene trisulfonate as a function of, and which can be correlated to, the amount of the glycohydrolytic enzyme present in the test sample; and (b) measuring and correlating either the intensity of fluorescence, or the optical density, of the test solution to the presence or amount of the glycohydrolytic enzyme in the test sample.
- the test sample can be selected from a variety of fluids or tissue, which include, but are not intended to be limited to, plasma, serum, ascites fluid, lymphatic fluid, cerebral spinal fluid, nipple fluid discharge, urine, gingival crevicular fluid, and the like.
- the test sample can also be selected from a variety of environmental or microbiological samples such as sewage, water, soil, oil, bacterial cultures, and the like, for the detection of bacterial glycosidases (Acta
- test sample can be diluted in a suitable diluent buffer,- such as phosphate buffered saline with serum components, to provide a sample volume that is required by a particular assay.
- a suitable diluent buffer such as phosphate buffered saline with serum components
- the test solution is excited with radiant energy having a wavelength of from between about 390 nm and about 490 nm wherein the selection of the appropriate wavelength will depend upon the pH of the test solution.
- the test solution is excited with radiant energy having a wavelength of from between about 410 nm for test solutions having a pH of about 5.0 or less and about 454 nm for test solutions having a pH of about 9.0 or greater.
- Such radiant energy causes 8-hydroxy-l,3,6-pyrene trisulfonate to fluoresce wherein the amount of fluorescence, which is measured at a wavelength of from between about 500 nm and about 530 nm, preferably at about 515 nm, can be correlated to the amount of the glycohydrolytic enzyme present in the test sample.
- the optical density of the test solution can be measured and correlated to the amount of the glycohydrolytic enzyme present in the test sample.
- such increase in optical density is measured at a wavelength of from between about 390 nm and about 490 nm wherein the selection of the appropriate wavelength will depend upon the pH of the test solution.
- the optical density is measured at a wavelength of from between about 410 nm for test solutions having a pH of about 5.0 or less and about 454 nm for test solutions having a pH of about 9.0 or greater.
- the measured changes in the optical density are the result of the liberated form of 8-hydroxy-l,3,6-pyrene sulfonate and can be correlated to the amount of the glycohydrolytic enzyme present in the test sample.
- a preferred embodiment of the present invention provides for the synthesis of pyrene-(l,3,6-trisulfonic acid)-8- ⁇ -D- glucuronide of the formula [VII] :
- the determination of ⁇ -D-glucoronidase is particularly useful for the diagnosis of periodontal disease wherein an elevated activity thereof in gingival crevicular fluid indicates acute inflammatory response.
- the compounds according to the present invention are significantly more soluble in water and aqueous systems than those substrates previously described, particularly for ⁇ '-glucuronidase, and a shift in the absorption and emission spectrum between the protonated form of the dye and the glycosides enables kinetic analysis at a pH of less than about 7.0.
- the present invention also provides other pyrene-(l ,3,6-trisulfonic acid) derivatives and the use thereof for determining other enzymes.
- Figure 1 illustrates an ' end-point fluorometric analysis for ⁇ -glucuronidase ( ⁇ G) and the amount of 8-hydroxy-l,3,6-pyrene trisulfonate (Pyr) formed as an end product (BG is expressed as enzyme activity using phenophthalein ⁇ -D-glucuronic acid [uIU]).
- Figure 2 illustrates a kinetic fluorometric analysis of ⁇ - glucuronidase hydrolysis of 1 ,3,6-pyrene trisulfonate-8- ⁇ -D- glucuronide.
- Figure 3 illustrates a kinetic absorption analysis of ⁇ - glucuronidase hydrolysis of 1 ,3,6-pyrene trisulfonate-8- ⁇ -D- glucuronide.
- the pyrano ring of the compounds that are described herein is represented as a six membered heterocyclic ring composed of five carbons and one oxygen, with a line extending above and below each of the carbons. Substituents other than hydrogen are shown at the end of each line that is above or below the relevant carbon to indicate that the isomer represented has that substituent above or below, respectively, the carbon to which it is bonded.
- Hydrogens attached directly to the carbons of the pyrano ring are not shown but, of course, are present wherever required to satisfy the four valences of the carbons-
- conventional numbering is used, the carbons of the pyrano ring being numbered in ascending order clockwise around the ring as viewed from above the paper on which it is represented, starting with the carbon adjacent the oxygen of the ring.
- the compound of formula VII it is the 1 carbon of the * pyrano ring to which the pyrene sulfonate is bonded through an ether linkage, and the bond from the 1 carbon to the oxygen of the ether linkage is above the pyrano ring.
- the 6 carbon is exocyclic, and is attached to the 5 carbon.
- the compound 1,3,6- pyrene trisulfonate-8- ⁇ -D-glucuronide [VII] is produced as described in Example 1 hereinbelow, and can be used to conduct a kinetic determination of, for example, ⁇ -glucuronidase activity.
- Such determination can be made by adding a 10 ⁇ L sample which contains ⁇ -glucuronidase to a 0.2 mL portion of a 0.3 mM solution of 1,3,6-pyrene trisulfonate-8- ⁇ -D-glucuronide [VII] in 0.1 M sodium acetate in deionized water, mixing thoroughly, and injecting the mixed sample into a fluorimetric flow cell which is temperature controlled at about 22.5°C while exciting at 410 nm and measuring emission at 515 nm. The initial rate of increase of fluorescence is proportional to the ⁇ -glucuronidase activity in the sample.
- a standard curve can be prepared from data derived by carrying out the procedure, using solutions of known, and varying, ⁇ - glucuronidase activity, and the standard curve can be used to determine ⁇ -glucuronidase activity from fluorescence data concerning unknown samples.
- the 1,3,6-pyrene trisulfonate-8- ⁇ -D-glucuronide [VII] can also be used to conduct a determination of ⁇ -glucuronidase activity by a procedure which involves determining a colorimetric endpoint. This determination can be made by adding a 50 ⁇ L sample which contains ⁇ -glucuronidase to 0.2 mL of a 0.3 mM solution of 1,3,6- pyrene trisulfonate-8- ⁇ -D -glucuronide [VII] in a 0.1 M solution of sodium acetate in deionized water, mixing thoroughly, incubating at 37°C for 15 minutes, quenching the reaction by adding 1.0 mL of a 0.25 M solution of glycine, pH 10.5, in deionized water, and measuring the optical density at 460 nm.
- optical density is proportional to the ⁇ -glucuronidase activity of the sample.
- a standard curve can be prepared from data collected from solutions containing known amounts of 8-hydroxy-l,3,6-pytene trisulfonate or from solutions containing known amounts of ⁇ -glucuronidase.
- a kinetic determination of ⁇ -glucuronidase activity by absorption can also be made using 1,3,6-pyrene trisulfonate-8- ⁇ -D- glucuronide [VII].
- a 50 ⁇ L sample which contains ⁇ -glucuronidase is added to 1.0 mL of a 0.1 mM solution of 1,3,6-pyrene trisulfonate-8- ⁇ -D-glucuronide [VII] in a 0.1 M solution of sodium acetate in deionized water (pH 4.25), mixing thoroughly, and measuring optical density at 410 nm continuously in a temperature controlled cell.
- the initial linear rate of increase in absorbance is proportional to the enzyme activity of the sample.
- a standard curve can be prepared from data collected from solutions containing known amounts of 8-hydroxy- 1,3,6-pyrene trisulfonate or from solutions containing known amounts of ⁇ -glucuronidase.
- a fluorescence endpoint determination of ⁇ -galactosidase activity can be made using 1,3,6-pyrene trisulfonate-8- ⁇ -D- galactoside as a substrate.
- 1,3,6-pyrene trisulfonate-8- ⁇ -D- galactoside is prepared as set forth in Example 4 below, and is of the formula [VIII]:
- 1,3,6-PYRENE TRISULFONATE-8- ⁇ -GALACTOSIDE To make this determination, 50 ⁇ L samples which contain ⁇ - galactosidase are added to 0.1 mL of a 1.0 mM 1,3,6-pyrene trisulfonate-8- ⁇ -D-galactoside [VIII] solution in 0.1 M 4- morpholinepropanesulfonic acid in deionized water. After incubation for 15 minutes at ambient temperature of about 22°C, the reaction is quenched by adding 2.0 mL of 0.25 M glycine, pH 10.5, vortexing each solution thoroughly, and measuring fluorescence emission at 515 nm after excitement in a fluorimetric cuvette at 454 nm.
- Emission at 515 nm is compared with a plot of intensity of emission at 515 nm as a function of 8-hydroxy-l,3,6-pyrene trisulfonate concentration or with a plot of intensity of emission at 515 nm as a function of ⁇ -galactosidase concentration.
- a fluorescence endpoint determination of ⁇ -glucosidase activity can be made using 1,3,6-pyrene trisulfonate- 8 - ⁇ -D-glucoside as a substrate.
- 1,3,6-pyrene trisulfonate-8- ⁇ -D-glucoside is prepared as set forth in Example 3 below, and is of the formula [DC]:
- Emission at 515 nm is compared with a plot of intensity of emission at 515 nm as a function of 8-hydroxy-l,3,6-pyrene trisulfonate concentration or with a plot of intensity of emission at 515 nm as a function of ⁇ -glucosidase concentration.
- Examples 1 and 3 demonstrate the production of pyrene-(l,3,6-trisulfonic acid)-8- ⁇ -D-glucuronide [VII] and of pyrene-(l ,3,6-trisulfonic acid)-8- ⁇ -D-glucoside [IX], respectively, compounds which differ from one another only with respect to the identity of the substituent on the 5 carbon, carboxyl in the former and CH2OH in the latter.
- the glucuronide was produced from bromo- 2,3,4-tri-O-acetyl- ⁇ -D-glucopyranuric acid methyl ester (methyl (tri- 0-acetyl( ⁇ )-D-glucopyranosyl bromide)-uronate [IV]), which is commercially available, and can also be produced by a method disclosed in BoUenback et al., supra.
- the glucoside was produced from 2,3,4,6-tetra-O-acetyl- ⁇ -D-glucopyranosyl bromide, which is also available commercially and, in addition, can be produced by the method of Koenigs and Knorr, Berichte der Deutschen Chemischenmaschine. Vol.
- a saccharide starting material that has a lactone or a carboxy group can be reacted to produce a methyl or another ester which is then reacted with the acetyl bromide, as in BoUenback, et al., to produce the corresponding O-acetyl bromide ester, which is then reacted with the pyrene sulfonate in the presence of the tetradecyl-trimethyl ammonium bromide or an equivalent.
- the tetradecyl-trimethyl ammonium bromide, or a suitable equivalent is used as a phase transfer catalyst in the synthesis.
- the pyrene sulfonate reacts minimally with either the acetyl bromide or the acetyl bromide ester.
- the O-acetyl bromide starting materials set forth in the Examples below can be produced from methyl ⁇ -D-glucuronate (Example 1), ⁇ -D- glucopyranose (Example 3), D-galactose (Example 4) and ⁇ -maltose (Example 5).
- saccharides that can be reacted with the acetyl bromide to produce a polyacetylated bromocarbohydrate or that can be reacted to produce a methyl of another ester which is then reacted with the acetyl bromide, as in BoUenback, et al., to produce a polyacetylated bromocarbohydrate, include the other anomers of the compounds of the present invention, other naturally occurring and synthetic sugars, e.g., erythrose, threose, ribose, arabinose, xylose, lyxose, allose, altrose, mannose, gulose, idose, talose, sucrose and lactose, the last two, like maltose, being disaccharides, and cellobiose (a disacchari.de), xylan (a polysaccharide) and polyglucuronic acid- (a poly saccharide), the last three occurring in
- the moiety represented by R in the formula of the compounds represented herein binds to one of the enzymes.
- the determination of ⁇ -glucuronidase, ⁇ -galactosidase or ⁇ - glucosidase in a sample, or the 8-hydroxy-l,3,6-pyrene sulfonate equivalence of those samples, as described herein is the result of the enzyme binding to the glucuronide, to the galactoside or to the glucoside, respectively, which causes hydrolysis thereof and the release of free 8-hydroxy-l,3,6-pyrene trisulfonate.
- the compounds of the present invention are also useful in other analytical test systems which require the measurement of the amount of enzyme present therein, particularly those analytical test systems employing enzyme-labeled assay reagents.
- Such other analytical systems include, but are not intended to be limited to, heterogeneous and homogeneous enzyme immunoassays known in the art, such as competitive, sandwich and immunometric techniques where the amount of enzyme label in a particular fraction thereof can be measured.
- immunoassay systems depend upon the ability of an immunoglobulin, i.e., a whole antibody or fragment thereof, to bind to a specific analyte wherein a conjugate comprising an antibody, or fragment thereof, to such analyte conjugated with a label or detectable moiety known in the art is employed to determine the extent of such binding.
- detectable moieties or labels include, but are not intended to be limited to, enzymes, chromogens, luminescent compounds, fluorescent compounds, and the like.
- the extent of binding is determined by the amount of the detectable moiety present in the conjugate which either has or has not participated in a binding reaction with the analyte, wherein the amount of the detectable moiety detected and measured can be correlated to the amount of analyte present in the test sample.
- the ⁇ -galactosidase activity of the conjugate can be determined by adding a substrate solution comprising 2 mM 1,3,6- pyrene trisulfonate-8- ⁇ -D-galactosidase, 1 mM magnesium chloride, and 10 mM 2-mercaptoethanol in 0.1 M potassium phosphate buffer, pH 7.0. Subsequent to the addition of the substrate, the enzyme- catalyzed hydrolysis is stopped with the addition of a volume of 2 M glycine, pH 10.5.
- a test kit according to the present invention comprises all of the essential reagents required to perform an assay for the determination of a glycohydrolytic enzyme as described herein.
- the test kit is presented in a commercially packaged form as a combination of one or more containers holding the necessary reagents, as a composition or admixture where the compatibility of the reagents will allow.
- test kit comprises a compound of the formula [VI], and may also include other materials as are known in the art and which may be desirable from a commercial user standpoint, such as buffers, diluents, standards, and the like.
- a particularly preferred test kit is for the determination of ⁇ - glucoronidase for the diagnosis of periodontal disease wherein such test kit comprises the compound of the formula [VII].
- Pyrene-(l,3,6-trisulfonic acid) -8 - ⁇ -D -Glucuronide [VII] was prepared from 8-hydroxy-l,3,6-pyrene trisulfonic acid trisodium salt (Eastman Kodak Co., Rochester, New York, USA) and bromo-2,3,4,-tri-0-acetyl- ⁇ -D-glucopyranuronic acid methyl ester (Sigma Chemical Co., St. Louis, Missouri, USA).
- the blue fluorescent fractions contained an acetyl protected intermediate product of the compound of formula [VII] wherein the CO2H group was CO2CH3, the three hydroxyls were OOCCH3 groups, and the three hydrogens were sodiums) were pooled and dried by rotoevaporation.
- the dried, acetyl protected intermediate product was dissolved in the sodium methoxide solution, and the solution was allowed to stand at room temperature of about 22°C for 4 hours, after which time an addition of 2.5 mL deionized water was made, and the solution was mixed thoroughly and allowed to stand at room temperature for about 15 hours.
- Cold acetone was then added to the solution to precipitate crude 1,3,6-pyrene trisulfonate-8- ⁇ -D- glucuronide [VII], which was further purified by dissolving in a small amount of deionized water and precipitating with cold methanol; the final product was recovered by filtration and dried, yielding 0.4 g product, 17 percent of theory.
- Solutions containing known amounts of 8-hydroxy-l ,3,6- pyrene trisulfonate were prepared, and 50 ⁇ L portions of each solution were mixed with 2.1 mL of 0.25 M glycine (pH 10.5) and placed in fluorimetric cuvettes and excited at 454 nm. Emission at 515 nm was measured for each solution, and the data were used to prepare a plot of intensity of fluorescence emission at 515 nm as a function of 8-hydroxy-l,3,6-pyrene trisulfonate concentration.
- Solutions containing known amounts of ⁇ -glucuronidase were also prepared, and were used to determine fluorescence at 515 nm as a function of ⁇ -glucuronidase concentration; 50 ⁇ L portions of each solution were added to 0.1 mL of 0.3 mM 1,3,6-pyrene trisulfonate- 8- ⁇ -D-glucuronide [VII] (prepared according to Example 1) in a 0.1 M sodium acetate solution in deionized water, and, after incubation for 15 minutes at ambient temperature of about 22°C, the reactions were quenched by adding 2.0 mL of 0.25 M glycine, pH 10.5.
- Samples containing ⁇ -glucuronidase were analyzed by adding 50 ⁇ L of each to 0-.1 mL of a 0.3 mM solution of 1 ,3.6-pyrene trisulfonate- 8- ⁇ -D-glucuronide [VII] in a 0.1 M sodium acetate solution in deionized water, and, after incubation for 15 minutes at ambient temperature of about 22°C, quenching the reaction by adding 2.0 mL of 0.25 M glycine, pH 10.5, vortexing each solution thoroughly, and measuring fluorescence at 515 nm after excitation in a fluorimetric cuvette at 454 nm.
- the 8-hydroxy-l,3,6-pyrene trisulfonate equivalence was determined by reference to the first curve (Table 1), while the ⁇ - glucuronidase content was determined by reference to the second (Table II).
- Example 3 The procedure described above in Example 3 was followed to produce 1 ,3,6-pyrene trisulfonate-8- ⁇ -D-galactoside [XIII] by substituting 0.6 grams 2,3,4,6-tetra-O-acetyl- ⁇ -D-galactosyl bromide for bromo-2,3,4,6-tetra-0-acetyl- ⁇ -D-glucopyranosyl bromide in the procedure of Example 3.
- Example 3 The procedure described above in Example 3 was followed to produce 1,3,6-pyrene trisulfonate-8- ⁇ -D-maltoside [X] by substituting 1.2 g ⁇ -bromohepta-O-acetylmaltose for bromo-2,3,4,6- tetra-O-acetyl- ⁇ -D-glucopyranosyl bromide in the procedure of Example 3.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne de nouveaux dérivés de trisulfonate de pyrène et leur utilisation selon un procédé de détermination de l'activité d'une enzyme glycohydrolytique. Le procédé consiste à (a) préparer une solution à examiner comprenant un échantillon à examiner contenant l'enzyme glycohydrolytique et un dérivé de trisulfonate de pyrène selon la présente invention, ce dérivé étant hydrolisé par l'enzyme glyclohydrolitique pour former un trisulfonate libre de 8-hydroxy-1,3,6-pyrène qui est fonction de la quantité d'enzyme glycohydrolytique présente dans l'échantillon à analyser et qui peut être mise en corrélation avec ladite quantité; et (b) à mesurer soit l'intensité de la fluorescence, soit l'intensité optique de la solution à analyser et à mettre en corrélation la valeur obtenue avec la présence ou la quantité d'enzyme glycohydrolytique dans l'échantillon à analyser. Un dérivé préféré de trisulfonate de pyrène est un pyrène-(acide 1,3,6-trisulfonique)-8-β-D-glucuroconjugué utilisé pour la détermination de l'activité de la β-D-glucoronidase dans le diagnostic d'une paradontolyse.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019940703768A KR950701255A (ko) | 1992-04-23 | 1993-04-23 | 잔류물 함유 포장용기의 처리방법 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/827,669 US5272260A (en) | 1992-01-29 | 1992-01-29 | Reagents and methods for the determination of glycohydrolytic enzymes |
| US07/827,669 | 1992-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1993015097A1 true WO1993015097A1 (fr) | 1993-08-05 |
Family
ID=25249825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1993/000988 WO1993015097A1 (fr) | 1992-01-29 | 1993-01-28 | Reactif et procede pour la determination de l'activite d'enzymes glycohydrolitiques |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US5272260A (fr) |
| WO (1) | WO1993015097A1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000003034A3 (fr) * | 1998-07-10 | 2000-04-27 | Chromagen Inc | Nouveaux substrats fluorogenes pour enzymes hydrolytiques |
| WO2007024945A1 (fr) | 2005-08-25 | 2007-03-01 | Novartis Ag | Derives imidazolo condenses utilises pour inhiber l'aldosterone synthase et l'aromatase |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063588A (en) * | 1996-11-14 | 2000-05-16 | The Trustees Of Columbia University In The City Of New York | Method of diagnosing periodontal disease |
| US5998593A (en) * | 1998-03-10 | 1999-12-07 | Abbott Laboratories | Fluorescent enzyme substrates |
| US6534637B2 (en) | 2001-02-12 | 2003-03-18 | Beckman Coulter, Inc. | Synthesis of chlorophenol red glucuronic acid |
| US20060088722A1 (en) * | 2004-10-25 | 2006-04-27 | Aller Robert C | Optical pH sensor |
| US7951603B2 (en) * | 2005-03-31 | 2011-05-31 | The Noguchi Institute | Method of mass spectrometric analysis of saccharides with aldehyde groups using labels containing a pyrene ring and a hydrazide group |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4830961A (en) * | 1986-06-05 | 1989-05-16 | Board Of Governors Of Wayne State University | Method and test kit for analysis of histamine receptor sites of mammalian cells |
| US4912208A (en) * | 1987-06-29 | 1990-03-27 | Abbott Laboratories | Fluorophores for encapsulation into liposomes |
| US5102808A (en) * | 1986-06-05 | 1992-04-07 | Board Of Governors Of Wayne State University | Method and test kit for analysis of histamine receptor sites of mammalian cells |
-
1992
- 1992-01-29 US US07/827,669 patent/US5272260A/en not_active Expired - Fee Related
-
1993
- 1993-01-28 WO PCT/US1993/000988 patent/WO1993015097A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4830961A (en) * | 1986-06-05 | 1989-05-16 | Board Of Governors Of Wayne State University | Method and test kit for analysis of histamine receptor sites of mammalian cells |
| US5102808A (en) * | 1986-06-05 | 1992-04-07 | Board Of Governors Of Wayne State University | Method and test kit for analysis of histamine receptor sites of mammalian cells |
| US4912208A (en) * | 1987-06-29 | 1990-03-27 | Abbott Laboratories | Fluorophores for encapsulation into liposomes |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000003034A3 (fr) * | 1998-07-10 | 2000-04-27 | Chromagen Inc | Nouveaux substrats fluorogenes pour enzymes hydrolytiques |
| US6635435B1 (en) | 1998-07-10 | 2003-10-21 | Chromagen, Inc. | Fluorogenic substrates and their use |
| US6949632B2 (en) | 1998-07-10 | 2005-09-27 | Chromagen, Inc. | Fluorogenic substrates |
| WO2007024945A1 (fr) | 2005-08-25 | 2007-03-01 | Novartis Ag | Derives imidazolo condenses utilises pour inhiber l'aldosterone synthase et l'aromatase |
Also Published As
| Publication number | Publication date |
|---|---|
| US5272260A (en) | 1993-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1436411B1 (fr) | Substrats chromogenes pour enzymes et methode de detection de l'activite beta-d-ribofuranosidase | |
| EP0157384B1 (fr) | Substrats pour hydrolases, leur méthode de préparation et leur emploi | |
| DE68915267T2 (de) | Enzymatisch kontrolliertes freisetzungssystem. | |
| US5292669A (en) | Agents for the detection of substrates with hydrolase activity | |
| US7563592B2 (en) | Alizarin-based chromogenic substrates, their uses and composition containing same | |
| JPH02160771A (ja) | レゾルフイン誘導体 | |
| EP0146866B1 (fr) | Phénylsulphonphtaleinyl-bêta-D-galactosides, leur méthode de préparation et leur emploi pour la détermination de la bêta-D-galactosidase | |
| US5272260A (en) | Reagents and methods for the determination of glycohydrolytic enzymes | |
| US5202233A (en) | Process for the detection of substances with hydrolase activity | |
| JPS58994A (ja) | 新規N−アセチル−β−D−グルコサミン誘導体およびこれを基質として用いるN−アセチル−β−D−グルコサミニダ−ゼ活性測定法 | |
| KR920000058B1 (ko) | 가수분해효소 활성을 갖는 물질들의 검출방법 및 약품 | |
| US6534637B2 (en) | Synthesis of chlorophenol red glucuronic acid | |
| US5260428A (en) | Agent for the detection of substances with hydrolase activity | |
| EP0223162A2 (fr) | Glucosides, leur procédé de préparation et procédé et moyen de détection et de détermination photométrique et fluorométrique des enzymes dégradant le sucre (glucosidases) | |
| WO2004085480A2 (fr) | Procedes et compositions pour l'essai d'hydrates de carbone | |
| EP0402699A2 (fr) | Substrats d'enzymes dibenzoxazépinone et dibenzothiazépinone chromogéniques | |
| Ogawa et al. | Isopropylidine maltoheptosyl fructofuranoside, doubly blocked substrate for determination of endoamylase activity | |
| WO2000029419A1 (fr) | Substrats chimiluminescents pour neuraminidase, dosages de detection de neuraminidase et kits afferents | |
| WO2025008744A1 (fr) | Substrat enzymatique fluorescent et ses procédés d'utilisation | |
| O'neal et al. | Fluorescence polarization immunoassay of Kanamycin | |
| EP0292169A2 (fr) | Substrates pour bêta-galactosidase | |
| CA1148080A (fr) | Methode de dosage faisant appel a une liaison specifique et employant comme marqueur un substrat fractionne par un enzyme | |
| CN109810019A (zh) | 一类化合物及其制备方法与作为荧光传感器的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |